Clinical therapeutic Evaluation of moxibustion in the treatment of moderate to severe primary knee osteoarthritis by using moxa from different habitats

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-IIR-16008359

Enrollment

Unknown

Registered

2016-04-26

Start date

2016-05-01

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Knee Osteoarthritis

Interventions

Moxa 1:Using Qichun moxa to treat

Moxa 2:Using Nanyang moxa to treat

Non-moxa:Using Yinchen to treat

Eligibility

Sex/Gender

All

Age

50 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. In the age of 50 to 80 years old; 2. Corresponding to the diagnostic criteria for primary knee osteoarthritis; 3. Drug(NSAID, analgesic, and traditional chinese medicine and Chinese patent medicine used to treat knee osteoarthritis) elution for 3 days. With a WOMAC osteoarthritis index total at more than 48 and equal to or less than 72, which rank moderate to severe in the knee osteoarthritis classification; 4. A plain radiograph evaluated as ?or ? of the Kellgren–Lawrence grade.

Exclusion criteria

Exclusion criteria: 1. Secondary knee osteoarthritis; 2. Target knee suffered from trauma or surgical history in the past year, with severe joint deformities( Genu varum or valgum>=8 degree); 3. Target knee received articular cavity glucocorticoid injection in the past 3 months, or sodium hyaluronate injection in the past 2 weeks, or acupuncture or moxibustion in the past 2 weeks; 4. With symptomatic coxarthria or patellofemoral arthritis of the homolateral target knee; 5. Inflammatory disease or other rheumatic diseases; 6. With acute meniscus injury or acute knee ligament injury/rupture; 7. Tumor, tuberculosis or spontaneous osteonecrosis around the knee; 8. With other diseases that need acetaminophen, NSAID or analgesic; 9. With uncontrolled hypertension or diabetes, severe cardiovascular and cerebrovascular disease, lung, liver, spleen, kidney and hematopoietic system disease, tumor, hemorrhagic disease and mental disease; 10. Cicatricial diathesis or esthesiodermia; 11. Pregnant or lactating women; 12. Refuse to sign the informed consent.

Design outcomes

Primary

Measure	Time frame
The baseline, the 2rd week and the 6th week's WOMAC pain score;The baseline, the 2rd week and the 6th week's VAS pain score;	—

Secondary

Measure	Time frame
WOMAC osteoarthritis index score;WOMAC Stiffness score;WOMAC Joint Function score;The proportion of clinical improvement;Patient's general assessment;The knee joint fluid amount;	—

Countries

China

Contacts

Public ContactShi Yin

flysy0636@163.com+86 13816042916

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026